常山药业(300255) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 reached ¥710,471,945.23, representing a 78.36% increase compared to ¥398,337,913.55 in the same period last year[8] - Net profit attributable to shareholders was ¥68,564,864.13, up 40.56% from ¥48,781,306.45 year-on-year[8] - Basic earnings per share increased to ¥0.07, reflecting a 40.00% rise from ¥0.05 in the same quarter last year[8] - The company's operating revenue for Q1 2021 reached 710.47 million CNY, an increase of 78.36% compared to the same period last year[26] - The net profit attributable to the parent company was 68.56 million CNY, reflecting a growth of 40.56% year-on-year[24] - The company's net profit for the first quarter is not explicitly stated, but the increase in revenue and costs suggests a focus on growth despite rising expenses[66] - The net profit for the current period was ¥66,736,639.13, up 51.5% from ¥44,080,297.75 in the previous period[76] - The total comprehensive income for the current period was ¥66,736,639.13, compared to ¥44,080,297.75 in the previous period, indicating a 51.5% increase[79] - The company's operating profit was ¥75,714,852.21, which is a 45.7% increase from ¥51,991,135.14 in the previous period[76] - The company reported a total profit of ¥75,614,852.21, an increase of 54.6% from ¥48,906,306.47 in the previous period[76] Cash Flow - The net cash flow from operating activities was ¥74,511,494.41, a significant recovery from a negative cash flow of ¥-307,050,623.24 in the previous year, marking a 124.27% improvement[8] - Cash flow from operating activities saw a net inflow increase of 124.27% year-on-year, driven by higher cash receipts from sales[25] - The cash flow from operating activities was ¥765,419,716.52, compared to ¥434,520,472.49 in the previous period, marking a 76% increase[80] - The net cash flow from operating activities was CNY 74.51 million, a turnaround from a negative CNY 307.05 million in the previous period[84] - The company reported a significant increase in sales cash receipts to CNY 741.14 million, compared to CNY 454.37 million in the previous period[87] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,606,218,350.24, a 0.74% increase from ¥4,572,556,783.14 at the end of the previous year[8] - The total assets of the company increased from ¥4,522,331,607.46 to ¥4,616,811,957.19, marking a growth of approximately 2.1%[63] - The total liabilities decreased to CNY 1,685,339,999.78 from CNY 1,719,328,775.53, a decline of about 2.0%[53] - Total liabilities rose from ¥1,664,068,858.42 to ¥1,691,812,569.02, an increase of about 1.7%[63] Shareholder Information - The top shareholder, Gao Shuhua, holds 35.69% of the shares, with a total of 333,644,728 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[15] Research and Development - Research and development expenses rose by 72.83% compared to the previous year, indicating increased investment in R&D[23] - Research and development expenses for the first quarter were ¥40,999,115.40, up from ¥23,722,505.21, indicating a significant increase of about 72.6% as the company invests in innovation[66] - Research and development expenses rose to ¥36,681,300.67, up 55.2% from ¥23,614,703.22, highlighting the company's commitment to innovation[73] Other Income and Expenses - The company reported a government subsidy of ¥3,180,483.63 during the reporting period[8] - Other income increased by 84.22% year-on-year, mainly due to higher government subsidies related to operating activities[23] - The income tax expense for the current period was ¥8,878,213.08, compared to ¥4,826,008.72 in the previous period, reflecting a 83.5% increase[76] - The company recorded other income of ¥2,847,937.70, which is an increase from ¥1,046,471.19 in the previous period, indicating a growth of 172.5%[73] Inventory and Accounts Receivable - Accounts receivable financing increased by 122.24% from the beginning to the end of the period, primarily due to an increase in outstanding bills[22] - Accounts receivable decreased to CNY 360,573,362.98 from CNY 387,300,920.58, indicating a reduction of about 6.9%[47] - Inventory increased to CNY 1,901,517,923.91 from CNY 1,886,950,438.19, showing a growth of approximately 0.8%[47] - Accounts receivable increased from ¥397,924,112.88 to ¥417,083,134.30, reflecting a rise of about 4.3%[57] - Inventory levels remained stable, with a slight increase from ¥1,757,827,045.66 to ¥1,758,844,500.20, indicating a focus on maintaining stock levels[57]